Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

5.9%

14 terminated/withdrawn out of 237 trials

Success Rate

89.1%

+2.6% vs industry average

Late-Stage Pipeline

19%

45 trials in Phase 3/4

Results Transparency

8%

9 of 115 completed trials have results

Key Signals

20 recruiting9 with results7 terminated7 withdrawn

Enrollment Performance

Analytics

Phase 2
55(34.0%)
N/A
51(31.5%)
Phase 3
36(22.2%)
Phase 1
11(6.8%)
Phase 4
9(5.6%)
162Total
Phase 2(55)
N/A(51)
Phase 3(36)
Phase 1(11)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (237)

Showing 20 of 237 trials
NCT05886504Not ApplicableCompleted

Drug Use & Infections in ViEtnam: Mental Health Intervention for INjecting Drug Users

Role: lead

NCT02626286Not ApplicableCompleted

Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa

Role: lead

NCT03459157Not ApplicableCompleted

Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)

Role: lead

NCT01509508Not ApplicableCompleted

Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence

Role: lead

NCT02038842Phase 1Completed

Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers

Role: lead

NCT00265642Phase 3Completed

Evaluation of Irbesartan on Hepatic Fibrosis in Chronic Hepatitis C

Role: lead

NCT03256422Phase 3Completed

Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients

Role: lead

NCT02107365Phase 2Completed

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Role: lead

NCT01453192Phase 3Completed

Renal Transplantation and Raltegravir in HIV-Infected Patients

Role: lead

NCT04133012Not ApplicableCompleted

Cartography of Virologic Reservoir Related to Antiretroviral Concentrations in HIV-1 Chronic Patients Treated by a First Line Treatment Containing Dolutegravir and Associated Nucleoside / Nucleotide Reverse Transcriptase Inhibitors Backbone

Role: lead

NCT00490074Phase 1Completed

Study to Compare the Immunogenicity and Safety of Two HIV Preventive Vaccinations in Healthy Volunteers

Role: lead

NCT01332955Phase 2Completed

Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen

Role: lead

NCT01420523Phase 2Terminated

Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy

Role: lead

NCT01605890Phase 2Completed

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Role: lead

NCT07113106Phase 1Recruiting

Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers

Role: lead

NCT07402044Not Yet Recruiting

CABOTEGRAVIR/LENACAPAVIR DUAL LONG ACTING THERAPY (COHORT IMEA 074)

Role: collaborator

NCT07419373Phase 2Recruiting

ARN-75039 Lassa Fever Treatment in West Africa

Role: collaborator

NCT05587894Phase 2Recruiting

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients: a Randomized Factorial Controlled Strategy Trial

Role: lead

NCT07406217Phase 2Recruiting

OPtimisation of Antiviral Therapy in Immunocompromised COVID-19 Patients

Role: collaborator

NCT07412977Not Yet Recruiting

"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"

Role: lead